医学
体内
抗血栓
外科
心脏病学
介入心脏病学
内科学
生物
生物技术
作者
Yuji Tanabe,Yukio Satô,Izumo Masaki,Yutaka Ishibashi,Takumi Higuma,Tomoo Harada,Yoshihiro Akashi
出处
期刊:PubMed
日期:2019-02-01
卷期号:31 (2): E44-E44
摘要
The current guidelines recommend a minimum of 6 months of antithrombotic and antibiotic prophylaxis following septal occluding device placement for transcatheter closure of atrial septal defect. Full neoendothelialization is thought to be completed within 6 months of device implantation; however, there is no method available that can assess the level of neoendothelialization in vivo. This report therefore evaluates endothelialization in vivo and demonstrates that 6 months of postimplantation prophylactic therapy may not provide sufficient time for adequate endothelialization. Further investigations are warranted to determine the optimal duration of these treatments after atrial septal defect closure.
科研通智能强力驱动
Strongly Powered by AbleSci AI